How to Own SpaceX Without Buying the IPO

SpaceX filed its S-1 on May 20, 2026, targeting a Nasdaq IPO at a $1.75 trillion to $2 trillion valuation, with 2025 revenue of $18 billion and Starlink contributing $11.4 billion, or 61% of sales. The article argues the IPO’s limited 5% float leaves little room for error, while suggesting indirect retail access through XOVR and DXYZ carries valuation and liquidity risks. It also highlights Rocket Lab as a lower-valuation public alternative, supported by a record launch backlog above $2.2 billion and projected Q2 revenue of $225 million to $240 million.

Analysis

The key market effect is not the IPO itself, but the repricing of the entire private-space complex around a new public reference point. A trillion-plus print would validate long-duration frontier infrastructure as a bona fide equity category, but it also compresses future return expectations across adjacent names because investors will anchor everything to SpaceX’s implied multiple of revenue and scarcity value. That creates a bifurcation: the asset-light, already-monetizing pieces of the ecosystem should benefit first, while pre-profitability satellite/launch stories become more vulnerable to “prove it now” scrutiny.

Rocket Lab is the cleanest second-order beneficiary because it offers operating leverage to space enthusiasm without the valuation gravity of the IPO lottery. The market will likely treat Neutron as the critical proof point: if the program stays on schedule into late 2026, the stock can re-rate on a credibility trade rather than a pure narrative trade. But because timing is now the whole story, any slip converts this from a growth asset into a disappointment asset very quickly; the window for upside is months, while the downside from execution delay can hit in days.

The more interesting contrarian angle is that the private-market wrappers may become less attractive, not more, after a headline-rich IPO. Once public markets give daily pricing to the category leader, stale marks and wide premiums in vehicles like DXYZ become easier to attack. XOVR is structurally better than DXYZ, but the SPV and valuation-lag issue means it still behaves more like a sentiment derivative than a clean exposure tool. That makes the trade less about owning SpaceX beta and more about avoiding vehicles where the embedded premium can evaporate if the IPO clears and secondary-market enthusiasm normalizes.

Key Decisions for Investors

• Long RKLB into the Neutron catalyst window, with a 3-6 month horizon; upside is a re-rating on execution credibility, while downside is concentrated in any launch delay or guidance miss.
• Use a pair trade: long RKLB / short DXYZ on SpaceX IPO enthusiasm; the thesis is that public operating proof should outperform premium-paying private-market wrappers if sentiment cools.
• Avoid initiating new long DXYZ positions at elevated premiums to NAV; the risk/reward is poor because the fund’s mark-to-market can compress faster than the underlying private assets can reprice.
• If seeking indirect SpaceX exposure, prefer XOVR over DXYZ, but size it as a tactical sentiment trade rather than a core holding; the cleaner structure still carries valuation-lag risk.
• For event-driven traders, buy RKLB call spreads expiring after the first Neutron launch window; this offers convexity to a successful milestone while limiting damage if the program slips.